Advanced Flower Capital Inc.

Good morning and welcome to ASCGamma's first quarter 2024 earnings call. At this time, all participants are in listening mode. Later, we will conduct a question and answer session and instructions will be given at that time. As a reminder, this call is being recorded. I would now like to turn the call over to Gabriel Katz, Chief Legal Officer. Please go ahead.

Good morning and thank you all for joining ASCGamma's earnings call for the quarter ended March 31st, 2024. I'm joined this morning by Daniel Neville, our Chief Executive Officer, Robin Tannenbaum, our President, and Brandon Hetzel, our Chief Financial Officer. Before we begin, I would like to note that this call is being recorded. Replay information is included in our April 10, 2024 press release and is posted on the investor relations portion of AFC Gamma's website at afcgamma.com, along with our first quarter earnings release and investor presentations. Today's conference call includes forward-looking statements and projections that reflect the company's current views with respect to, among other things, anticipated market developments, portfolio yield, and financial performance in 2024 and beyond. These statements are subject to inherent uncertainties in predicting future results. Please refer to AFC Gamma's most recent periodic filings with the SEC for certain conditions and significant factors that could cause actual results to differ materially from these forward-looking statements and projections. During this call, we will refer to distributable earnings, which is a non-GAAP financial measure. Reconciliations to net income, the most comparable GAAP measure, can be found in AFC Gamma's earnings release and investor presentation available on AFC Gamma's website. The format for today's call is as follows. Dan will provide an overview of our first quarter 2024 performance, as well as an update on our portfolio. Robin will then provide an update on the anticipated spinoff of our commercial real estate portfolio, and Brandon will conclude with a summary of our financial results. We will then open the lines for Q&A. With that, I will now turn the call over to our CEO, Dan Nebel.

Thank you, Gabe. Good morning, and welcome to AFC's earnings call for the quarter ended March 31st, 2024. I would like to thank everyone for joining us today to discuss our results. For the first quarter, AFC generated distributable earnings of 49 cents per basic weighted average share of common stock. As a reminder, distributable earnings is the primary metric the board considers when declaring quarterly dividends. The board of directors declared a fourth consecutive 48-cent dividend, which was paid on April 15, 2024, to shareholders of record as of March 31, 2024. Since going public, we have generated distributable earnings that met or exceeded our dividend each quarter and paid out $6.02 in dividends per share. We are increasingly optimistic about the outlook for the cannabis industry. The industry has seen expansion fueled by increasing state-by-state legalization and growing consumer acceptance. According to BDSA, the U.S. cannabis industry is projected to continue its upward trajectory with sales hitting $32 billion in 2024 and growing to $46 billion by 2028. We continue to see exciting developments at both the state and federal level. Just last week, the Attorney General put forth a proposal to reclassify cannabis from Schedule 1 to Schedule 3. Once enacted, this change would bring significant benefits to the U.S. cannabis industry, including the elimination of a punitive tax regime for cannabis and increased investment in the space. From a lender's perspective, we expect that the elimination of 280E will enhance the cash flow and credit profile for our existing borrowers and expand our pipeline of potential borrowers. Beyond the financial impact, the rescheduling process is a long overdue validation of the medical benefits of cannabis and yet another concrete step in the slow but steady march toward legalization. While there is still uncertainty related to the timeline for rescheduling, we are encouraged by the progress. At the state level, Ohio is anticipated to commence adult use sales by the end of June, months ahead of schedule. We believe that Ohio will be an exciting AU transition, as it currently has a strict medical program. Additionally, Florida is gearing up for a decision regarding legalizing cannabis for adult use, which will be on the upcoming November ballot. Across these two states, approximately 34 million Americans could potentially gain access to adult use cannabis in the next few years. As the first NASDAQ-listed cannabis lender and one of the leading debt providers in the space, ASC is uniquely positioned to capitalize on these opportunities. We have created a diversified portfolio across limited license dates with attractive supply-demand dynamics. As of March 1, 2024, our cannabis portfolio had a weighted average yield to maturity of 20%. We have good exposure to early-stage and expected near-term adult use transition states. As of May 1, 2024, over a third of our portfolio, based on commitments, has exposure to Ohio, Florida, and Pennsylvania. We are pleased to see how certain portfolio companies benefited from Missouri's transition to adult use. and believe that our portfolio is well positioned to benefit from these upcoming AU transition states as well. During the quarter, we originated $90 million of loans with $34 million of loans to cannabis operators and $56 million to commercial real estate developers. Our actionable pipeline of cannabis deals stands at $303 million and the origination team is now firing on all cylinders. We have one additional deal and documentation that we expect to close in the coming weeks, and we continue to have liquidity to make additional investments. And given the limited supply of institutional capital, we believe this will allow us to both move up the quality curve while still achieving mid- to high-teens IRRs. Before turning to our portfolio, I'd like to highlight a notable transaction that we closed in the first quarter. In March, AFC funded debt of $34 million to Sunburn Cannabis, a private vertically integrated single state operator in Florida. Sunburn represents AFC's second transaction in Florida's growing medical cannabis market. We are delighted to partner with the Sunburn team and believe that they exemplified the cannabis 3.0 operators that we've previously highlighted. This is a team with prior success in the Florida market that has significant experience scaling and operating cannabis businesses. We believe Sunburn is well positioned to continue to take market share in Florida, given its strong brand recognition. Now turning to the portfolio. During the quarter, we successfully exited Private Company I's loan, which was on non-accrual. As a reminder, we sold two-thirds of the loan in June 2023, and in March 2024, we were repaid on the remaining $3.8 million of principal under the loan at par. The loan generated an IRR of 24%, and is an example of our ability to actively manage the portfolio to achieve successful outcomes for our shareholders. Turning to private company B. Since entering receivership in October 2023, the company's operations and cash generation have improved under the receiver's management. Today, company B remains current on all interest payments, including default interest, and we are negotiating potential exit opportunities. As evidenced by these two scenarios, our hands-on portfolio management efforts are yielding tangible results. We remain optimistic about achieving similar favorable outcomes for our other underperforming loans in the portfolio as we continue to make progress in reducing our exposure to these credits. Subsidiary of private company G continues to make progress. Since the forbearance, the borrower has infused $3 million of additional equity capital and has paid over $2 million in interest. We are also starting to see improved performance at the borrower's Pennsylvania and New Jersey operations as a result of the experienced operators that have been put into place to manage the operations. Turning to subsidiary of public company H. In April 2024, the co-agents under the credit facility provided notice to the borrower citing certain defaults, including a breach of minimum cash covenants as of March 31st, 2024. Additionally, in May, the borrower failed to make the April interest payments. We are currently comfortable with our collateral, but given the company's liquidity position, we believe swift action is necessary to preserve the value of that collateral. As a reminder, our collateral package includes the business operations across 23 dispensaries and seven cultivation processors. This includes vertical operations in Ohio, New Jersey, Illinois, New York, Massachusetts, Maine, and soon to be Pennsylvania, once the additional three dispensary licenses are issued. It also includes real estate assets in Connecticut, assets with own cultivation real estate in both Ohio and Illinois. We intend to take all actions necessary to protect our capital on behalf of our investors. When I joined AFC in November, I emphasized my commitment to taking a hands-on approach to address issues at select underperforming portfolio companies. We have made progress in restructuring some underperforming credits, and we remain optimistic about achieving similar favorable outcomes for our other underperforming loans. Additionally, I am pleased with our origination efforts, with $90 million in deals closed during the quarter across both cannabis and commercial real estate. I look forward to continuing to update you on our progress. Now, I'll turn it over to Robin to provide an update on the spinoff in our commercial real estate portfolio.